DURECT (DRRX) Competitors $0.53 -0.03 (-5.34%) As of 07/15/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DRRX vs. VTGN, GNTA, RPTX, IRD, ANEB, IKNA, KLTO, CNTX, ASRT, and FBRXShould you be buying DURECT stock or one of its competitors? The main competitors of DURECT include VistaGen Therapeutics (VTGN), Genenta Science (GNTA), Repare Therapeutics (RPTX), Opus Genetics (IRD), Anebulo Pharmaceuticals (ANEB), Ikena Oncology (IKNA), Klotho Neurosciences (KLTO), Context Therapeutics (CNTX), Assertio (ASRT), and Forte Biosciences (FBRX). These companies are all part of the "pharmaceutical products" industry. DURECT vs. Its Competitors VistaGen Therapeutics Genenta Science Repare Therapeutics Opus Genetics Anebulo Pharmaceuticals Ikena Oncology Klotho Neurosciences Context Therapeutics Assertio Forte Biosciences DURECT (NASDAQ:DRRX) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends. Do insiders & institutionals have more ownership in DRRX or VTGN? 28.0% of DURECT shares are owned by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are owned by institutional investors. 3.2% of DURECT shares are owned by insiders. Comparatively, 1.3% of VistaGen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, DRRX or VTGN? DURECT has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, VistaGen Therapeutics has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Does the media prefer DRRX or VTGN? In the previous week, VistaGen Therapeutics had 2 more articles in the media than DURECT. MarketBeat recorded 3 mentions for VistaGen Therapeutics and 1 mentions for DURECT. VistaGen Therapeutics' average media sentiment score of 1.89 beat DURECT's score of 1.87 indicating that VistaGen Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment DURECT Very Positive VistaGen Therapeutics Very Positive Do analysts recommend DRRX or VTGN? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DURECT 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00VistaGen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is DRRX or VTGN more profitable? DURECT has a net margin of -91.54% compared to VistaGen Therapeutics' net margin of -6,777.08%. VistaGen Therapeutics' return on equity of -58.88% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets DURECT-91.54% -267.36% -64.00% VistaGen Therapeutics -6,777.08%-58.88%-52.38% Which has stronger valuation and earnings, DRRX or VTGN? DURECT has higher revenue and earnings than VistaGen Therapeutics. DURECT is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDURECT$2.03M8.11-$8.32M-$0.15-3.53VistaGen Therapeutics$486K134.99-$51.42M-$1.66-1.36 SummaryVistaGen Therapeutics beats DURECT on 9 of the 15 factors compared between the two stocks. Get DURECT News Delivered to You Automatically Sign up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRRX vs. The Competition Export to ExcelMetricDURECTMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.39M$2.44B$5.62B$9.30BDividend YieldN/A1.79%4.25%4.03%P/E Ratio-3.539.1428.5719.58Price / Sales8.11676.39423.3093.84Price / CashN/A164.3436.0257.93Price / Book1.834.608.135.54Net Income-$8.32M$30.99M$3.24B$257.73M7 Day Performance-18.18%-1.81%0.16%-0.08%1 Month Performance-16.05%5.73%5.95%8.09%1 Year Performance-61.01%-7.03%26.09%13.02% DURECT Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRRXDURECT1.2059 of 5 stars$0.53-5.3%N/A-60.7%$17.39M$2.03M-3.5380Positive NewsGap DownVTGNVistaGen Therapeutics1.0976 of 5 stars$2.38flatN/A-42.5%$69.40M$490K-1.4340Positive NewsGNTAGenenta Science2.6103 of 5 stars$3.78-4.5%$25.00+561.4%+10.0%$69.14MN/A0.007Gap UpRPTXRepare Therapeutics2.918 of 5 stars$1.57+4.7%$4.50+186.6%-60.3%$67.34M$53.48M-0.52180News CoveragePositive NewsIRDOpus Genetics1.8569 of 5 stars$1.11-1.8%$7.33+560.7%N/A$66.22M$10.99M-0.5314Analyst UpgradeANEBAnebulo Pharmaceuticals2.7155 of 5 stars$1.61-3.0%$5.50+241.6%-35.1%$66.15MN/A-6.194Positive NewsGap DownIKNAIkena Oncology2.7664 of 5 stars$1.37-0.7%$3.00+119.0%-16.5%$66.11MN/A-1.5970News CoverageGap UpHigh Trading VolumeKLTOKlotho NeurosciencesN/A$1.25-3.8%N/AN/A$65.88MN/A-3.47N/ACNTXContext Therapeutics3.3186 of 5 stars$0.73+9.3%$5.50+651.2%-66.6%$65.68MN/A-2.367Positive NewsASRTAssertio1.8589 of 5 stars$0.69-0.8%$2.75+301.1%-57.1%$65.68M$124.96M-2.1420Negative NewsFBRXForte Biosciences3.4941 of 5 stars$9.84-6.7%$61.00+519.9%+42,163.0%$64.75MN/A-0.605Positive News Related Companies and Tools Related Companies VTGN Competitors GNTA Competitors RPTX Competitors IRD Competitors ANEB Competitors IKNA Competitors KLTO Competitors CNTX Competitors ASRT Competitors FBRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRRX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share DURECT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DRRX Stock Alerts